Table 6.

Recommendations for stakeholders

Based on this survey, we recommend that CSOs:

• conduct HCV epidemiology studies in key populations;

• integrate HCV services in PWID and PLHIV programs;

• monitor PWID access to HCV treatment; document, disseminate and, if appropriate, pursue legal and media options for any cases of service denial;

• advocate for inclusion of PWID in national HCV guidelines and programs;

• advocate for HCV medication price reductions through stakeholders and the media;

• monitor the drug registration landscape and maintain pressure on pharmaceutical companies and governments for prompt registration of new drugs;

• partner with international organizations to oppose barriers and leverage TRIPS flexibilities;

• work with governments on regulatory measures to ensure lower prices for generics;

• advocate for government disclosure of prices, purchase volumes and relevant treatment program details to allow independent expert evaluation;

• participate on national HCV program advisory committees;

• participate in advocacy related to keeping WHO guidelines updated;

• include HCV testing and treatment in project proposals, with focus on key populations but also considering the general population;

• document and disseminate CSO-led HCV program best practices.